 | • レポートコード：B-MOR-06006 • 出版社/出版日： / 2018年6月20日 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・製薬 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、無針（ニードルフリー）ドラッグデリバリーの世界市場について調べ、無針（ニードルフリー）ドラッグデリバリーの世界規模、市場動向、市場環境、技術別分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・無針（ニードルフリー）ドラッグデリバリーの世界市場インサイト ・無針（ニードルフリー）ドラッグデリバリーの世界市場環境 ・無針（ニードルフリー）ドラッグデリバリーの世界市場動向 ・無針（ニードルフリー）ドラッグデリバリーの世界市場規模 ・無針（ニードルフリー）ドラッグデリバリーの世界市場規模：技術別 ・無針（ニードルフリー）ドラッグデリバリーの世界市場規模：用途別 ・無針（ニードルフリー）ドラッグデリバリーの世界市場：地域別市場規模・分析 ・無針（ニードルフリー）ドラッグデリバリーの北米市場規模・予測 ・無針（ニードルフリー）ドラッグデリバリーのアメリカ市場規模・予測 ・無針（ニードルフリー）ドラッグデリバリーのヨーロッパ市場規模・予測 ・無針（ニードルフリー）ドラッグデリバリーのアジア市場規模・予測 ・関連企業情報・競争状況 |
The global needle-free drug delivery devices market is expected to register a CAGR of approximately 9.7% over the forecast period of 2018-2023. Needle-free drug delivery injects the biologics without pain, anxiety, and need for handling the needles, and the market studied is primarily driven by the prevalence of chronic diseases and technological advancements in the field. By region, owing to the presence of a large target population suffering from chronic diseases, improving healthcare infrastructure in several countries, and prospering economies attracting multinational biopharmaceutical companies to invest in India, China, and other South Asian countries, it is estimated that Asia-Pacific has a high-growth potential during the forecast period.
Inclination toward Self-administration of Drugs
As modern lifestyle encourages independence, the way people use medications also gets affected. Self-administration of insulin is the state-of-the-art technology in diabetes care. Although with through technological development, the process is also advancing toward other medical areas, such as oncology and hormone therapy. The recent years have witnessed a high demand for pens and auto-injectors. There are several universities, hospitals, and research centers, which are collaborating and sponsoring the trials for needle-free jet injection across the globe, mainly in the United States, United Kingdom, and China. In the later half of 2017, a spin-out, Portal Instruments of Massachusetts Institute of Technology, collaborated with Takeda Pharmaceuticals, for the development and commercialization of PRIME, for testing antibodies in patients with ulcerative colitis or Crohn’s disease. Therefore, with partnerships and technological advancements, the inclination toward self-administration of drugs is expected to boost the growth of the market studied, over the forecast period.
The other vitals factors driving the market studied are – rising prevalence of chronic diseases and lifestyle disorders and technological advancements in the minimally invasive devices market.
Limitations Associated with Micro-needle Patches
There are considerable limitations associated with micro-needle patches, in practical and economic terms. The micro-needle arrays have a restricted amount of drug that can be coated over a finite surface area of the micro-needle structures, thereby creating issues of adequate physio-chemical properties. In addition, the deposition of polymer in skin due to micro-needle, potential clogging of the needle openings with tissue during skin insertion, and flow resistance due to dense dermal tissue make them undesirable for use. Moreover, the silicon used is expensive and have elaborated fabrication, long fabrication times, and complex multi-step processing. There are several other associated restrictions, creating significant variation in results, based on analysis of the micro-needle penetration. Thus, the barriers associated with the micro-needle patches limit the growth of the needle-free drug delivery devices market, over the forecast period.
Asia-Pacific Offers Significant Opportunities
Asia-Pacific is expected to promise considerable growth opportunities over the forecast period, in the market studied. Large patient pools of chronic diseases, particularly diabetes, cardiovascular diseases, and cancer, are major drivers in the emerging markets. Several universities and research centers across China, Thailand, Vietnam, and South Korea have collaborated with companies or hospitals, to conduct the trials registered in clinicaltrial.gov. These are funded by the governments and companies from the developed markets. Thus, over the forecast period, the region is expected to witness the highest growth rate.
Key Developments in the Market
• May 2018 – Antares Pharma Inc. received USD 4.75 million from Ferring Pharmaceuticals, for the sale of Antares’ worldwide rights for the Zomajet needle-free auto-injector device.
• May 2018 – Namaste Technologies signed a definitive agreement with Inolife R&D Inc., wherein Namaste is granted exclusive rights for needle-free technologies, for applications of medical cannabis.
Major Players: 3M, AKRA DERMOJET, ANTARES PHARMA, D’ANTONIO CONSULTANTS INTERNATIONAL INC., ENDO PHARMACEUTICALS INC., PENJET CORPORATION, PHARMAJET, VALERITAS INC., AND ZOGENIX INC., amongst others.
Reasons to Purchase this Report
• Current and future of needle-free drug delivery devices market in the developed and emerging economies
• Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• The regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report that suits your needs.
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
6.1.2 Inclination toward Self-administration of Drugs
6.1.3 Technological Advancements in Minimally Invasive Devices
6.2 Market Restraints
6.2.1 Stringent Regulatory Framework
6.2.2 Limitation Associated with the Use of Micro-needle Patches
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Technology
7.1.1 Inhaler
7.1.2 Jet Injector
7.1.3 Novel Needle
7.1.4 Transdermal Patch
7.1.5 Others
7.2 By Application
7.2.1 Insulin Delivery
7.2.2 Vaccination
7.2.3 Pain Management
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 3M
9.2 Akra Dermojet
9.3 Antares Pharma
9.4 D’Antonio Consultants International Inc.
9.5 Endo Pharmaceuticals Inc.
9.6 Penjet Corporation
9.7 PharmaJet
9.8 Valeritas Inc.
9.9 Zogenix Inc.
* List Not Exhaustive
10. Future of the Market